Gossamer Bio, Inc.

Gossamer Bio, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Gossamer Bio, Inc. has 6.11M shares outstanding.

As of June 30, 2026, Gossamer Bio, Inc. maintains a current ratio of 0.53, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -42.61, indicating conservative leverage, while an interest coverage ratio of -15.07 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -78.81, reflecting losses generated across the asset base. The company generates approximately 295,665.52 in revenue per employee across its workforce of 157.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Gossamer Bio, Inc. recorded an income tax benefit of -77,026.40 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -109.68M and -109.61M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Gossamer Bio, Inc. generated 46.64M in revenue and converted that into -109.61M in net income, yielding earnings per share of -34.47. EBITDA reached -144.57M, while operating income came in at -138.84M.

As of June 30, 2026, Gossamer Bio, Inc. holds 49.91M in cash and equivalents against 35.07M in total debt, resulting in a net debt position of -4.38M. Total book value stands at -82.30M, with working capital of -56.95M providing operational flexibility.

Gossamer Bio, Inc. produced -142.35M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -142.35M - equivalent to -45.16 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -297.67 and net profit margin of -235.00 provide insight into operational efficiency.

Gossamer Bio, Inc.'s most recent stock split took place on September 11, 2026 with a 80:1 split ratio.